Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

Joshua S. Kaplan a,*, Nephi Stella a,b,1, William A. Catterall a,1,2, and Ruth E. Westenbroek a,1

aDepartment of Pharmacology, University of Washington, Seattle, WA 98195; and bDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195

Contributed by William A. Catterall, September 7, 2017 (sent for review July 3, 2017; reviewed by Lori L. Isom, Daniele Piomelli, and Peter C. Ruben)

Worldwide medicinal use of cannabis is rapidly escalating, despite limited evidence of its efficacy from preclinical and clinical studies. Here we show that cannabidiol (CBD) effectively reduced seizures and autistic-like social deficits in a well-validated mouse genetic model of Dravet syndrome (DS), a severe childhood epilepsy disorder caused by loss-of-function mutations in the brain voltage-gated sodium channel Na v1.1. The duration and severity of thermally induced seizures and the frequency of spontaneous seizures were substantially decreased. Treatment with lower doses of CBD also improved autistic-like social interaction deficits in DS mice. Phenotypic rescue was associated with restoration of the excitability of inhibitory interneurons in the hippocampal dentate gyrus, an important area for seizure propagation. Reduced excitability of dentate granule neurons in response to strong depolarizing stimuli was also observed. The beneficial effects of CBD on inhibitory neurotransmission were mimicked and occluded by an antagonist of GPR55, suggesting that therapeutic effects of CBD are mediated through this lipid-activated G protein-coupled receptor. Our results provide critical preclinical evidence supporting treatment of epilepsy and autistic-like behaviors linked to DS with CBD. We also introduce antagonism of GPR55 as a potential therapeutic approach by illustrating its beneficial effects in DS mice. Our study provides essential preclinical evidence needed to build a sound scientific basis for increased medical use of CBD.

Significance

Medicinal cannabis use is booming despite limited preclinical evidence and mechanistic insight. Recent clinical trials of cannabidiol (CBD) in Dravet syndrome (DS) support its clinical efficacy for reduction of seizure frequency and invite study of its benefits for additional DS symptoms. We demonstrate here that treatment with CBD is beneficial for seizure frequency, duration, and severity and for autistic-like social deficits in a mouse model of DS. CBD rescue of DS symptoms is associated with increased inhibitory neurotransmission, potentially mediated by antagonism of the lipid-activated G protein-coupled receptor GPR55. These studies lend critical support for treatment of seizures in DS with CBD, extend the scope of CBD treatment to autistic-like behaviors, and provide initial mechanistic insights into CBD’s therapeutic actions.

Author contributions: J.S.K., N.S., W.A.C., and R.E.W. designed research; J.S.K. and R.E.W. wrote the paper.

Reviewers: L.L.I., University of Michigan Medical School; D.P., University of California, Irvine; and P.C.R., Simon Fraser University. The authors declare no conflict of interest.

1N.S., W.A.C., and R.E.W. contributed equally to this work.

2To whom correspondence should be addressed. Email: wcatt@uw.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711351114/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1711351114
PNAS Early Edition | 1 of 6

Globally increasing medicinal use of cannabis is rapidly escalating (www.unodc.org/wdr2017/) (1). In particular, extracts rich in cannabidiol (CBD), an abundant bioactive but nonpsychotomimetic constituent of Cannabis sativa, are increasingly used to treat refractory epilepsy (2). However, there is only limited evidence for its efficacy in preclinical models (3, 4) and human studies (5–7). Recent clinical trials found that CBD reduced seizure frequency in patients with DS and other treatment-refractory epilepsies (6, 7). However, preclinical studies of CBD in validated animal models can provide quantitative measures of CBD’s efficacy in controlling seizure duration and severity in addition to frequency. Studies in animal models can also assess potential beneficial effects of CBD on the behavioral comorbidities of Dravet syndrome (DS) and probe the underlying physiological and molecular mechanisms mediating these therapeutic effects. Heterozygous loss-of-function mutations in SCN1A cause DS, a severe childhood neuropsychiatric disorder characterized by treatment-refractory epilepsy, autism, other comorbidities, and frequent premature death (8–10). The uncertainty of seizure onset; the increasing frequency, duration, and intensity of seizures; and the risk of injury is an immense source of anxiety for parents (11, 12). Moreover, the ensuing social impairment associated with DS adds an additional burden of care and increases risk for accidents and premature death (9, 10). Thus, pharmacological rescue of both epilepsy and autism-related behaviors would greatly increase the quality of life for DS patients and their caregivers.

Scn1a +/− mice (DS mice) are a well-defined phenocopy of human DS (13, 14), as they exhibit both thermally induced and spontaneous seizures (13, 15) and autism-like social deficits (16, 17). Previous work showed that DS symptoms result from the loss-of-function of Na v1.1 channels, which selectively reduces sodium current and excitatory drive in many types of GABAergic interneurons (13, 14, 18–20). Accordingly, targeting the Scn1a mutation to Na v1.1 channels in forebrain GABAergic interneurons recapitulated the DS phenotype and established that hypoexcitability of these interneurons is sufficient to cause the epileptic phenotype (21) and autistic-like behaviors (16) observed in DS mice. In contrast, targeting the Scn1a mutation to excitatory neurons ameliorates DS in mice, which is opposite to the effects of gene disruption in inhibitory neurons (22). Additional effects of compensatory changes in gene expression, electrical excitability, and genetic background also have a strong influence on epileptic phenotypes of DS mice (SI Discussion). These results suggest that effective treatment of DS could potentially be achieved through enhancing GABAergic signaling by inhibitory neurons (16, 23) or selectively decreasing electrical excitability in excitatory neurons (24).

Given the promising results for CBD in treating seizures in DS, coupled with its low side-effect profile, we have analyzed its effects on epilepsy and autistic-like behaviors in DS mice. Here we report that CBD substantially reduces the frequency, duration, and severity of seizures and ameliorates the impaired social interaction behaviors of DS mice. These beneficial effects are correlated with enhanced GABAergic neurotransmission, decreased excitation/inhibition ratio, and decreased action potential firing of excitatory neurons in response to strong stimuli. These changes in GABAergic neurotransmission are mimicked and occluded by inhibition of the lipid-activated G protein-coupled receptor
CBD reduced seizures in DS mice. The initial symptoms associated with DS are observed as early as 6--9 mo of age with the onset of febrile seizures, followed by spontaneous epileptic seizures with increasing severity and frequency (8, 9). We modeled febrile seizures by thermal induction in DS mice, in which core body temperature was slowly raised to 38 °C and held there for 30 min (15). Acute treatment with CBD (100 mg/kg or 200 mg/kg, i.p.) 1 h before thermal induction reduced the duration (Fig. 1A) and severity (Fig. 1B) of seizures. Such reduction in seizure severity to a Racine score of 3.5 or less is known to greatly reduce risk of sudden unexpected death in epilepsy in DS mice (21, 25). Because the half-life of CBD in rodents is much shorter than in humans (~4.5 h in mice (26); ~24 h in human (27)), it is difficult to precisely compare the 100--200 mg/kg effective i.p. dose range that we observed here with the 20--50 mg/kg oral dose range used in recent clinical trials (6, 7).

To test if repeated CBD administration protects against spontaneous seizures, we administered CBD (100 mg/kg) twice daily during the period of maximum seizure risk, postnatal days 21--28 (13, 14, 20, 22, 25). We measured seizure frequency in the 4-h interval following treatment while the plasma drug concentration remained at >50% of peak (26). Consistent with previous reports, vehicle-treated DS mice exhibited spontaneous seizures at a rate of 0.31 seizures/mouse/hour. Treatment with CBD reduced the spontaneous seizure rate by 70% (Fig. 1C), further supporting the efficacy of CBD in treatment of epilepsy in DS mice. Together, these results show that CBD protects against both febrile seizures and spontaneous seizures in a validated mouse genetic model of DS.

To test for potential adverse effects associated with 100 mg/kg CBD treatment, we measured the distance traveled and maximum velocity of movement of DS mice measured in the center of the open field (Fig. S1B). DS mice performed better on the rotorod than WT mice, and their performance was reduced to the WT level in the presence of 100 mg/kg CBD (Fig. S1C). One interpretation of these results is that the hyperactivity of DS mice improves their performance on the rotorod compared with WT due to their more frenetic efforts to stay on the rotatrod, and this advantage is lost upon CBD treatment because it reverses their hyperactivity. Together, these results suggest that 100 mg/kg CBD has a therapeutic effect to reverse hyperactivity of DS mice but does not have a significant adverse effect to impair motor function and coordination compared with untreated WT mice.

CBD Rescues Autistic-Like Social Interaction Deficits in DS Mice. In both humans diagnosed with DS and in our mouse genetic model of DS, the frequency and severity of seizures abate following sexual maturity, while severe social deficits that are characteristic of autism persist (8--10, 16). Social/behavioral outcomes have not been measured in previous studies of CBD in DS (6, 7). To test CBD’s efficacy in treating autistic-like behaviors in DS mice, we used the Three-Chamber Test of social interaction (29) in which DS mice show profound deficits compared with WT littermates (16). We found that low doses of CBD (10 mg/kg or 20 mg/kg) administered i.p. 1 h before testing increased the proportion of time that DS mice spent interacting with the stranger mouse in the Three-Chamber Test, suggesting a rapid reversal of this autistic-like behavioral deficit (Fig. 2A). Importantly, treatment with these low doses of CBD did not impact locomotor activity in the open field (Fig. 2B). Surprisingly, we found that higher doses of CBD did not produce this beneficial effect (Fig. 2A), consistent with prior studies showing rescue of social deficits with low-dose benzodiazepine treatment in DS mice but not with higher doses (16). In contrast, there was no effect of CBD in WT mice when assessing this same behavior (Fig. 2A).

To extend this result, we tested CBD’s impact in the Reciprocal Interaction Test, which assesses behavior in an open field in the response to direct physical interaction with a stranger mouse. DS mice treated with vehicle engaged in a similar number of social interactions with a stranger mouse as did WT mice (Fig. 2C). However, DS mice made more frequent defensive escapes following the social interaction (Fig. 2D), which is characteristic of these mice. Acute treatment with CBD (10 mg/kg) increased the number of social interactions of DS mice (Fig. 2D) and reduced the frequency of defensive escapes to WT levels (Fig. 2D). As in the Three-Chamber Test, there was no effect of CBD on WT mice when measuring similar behavior, suggesting that low doses of CBD significantly improve measures of social interaction only in the case of genetic deficit.
CBD improved social deficits in DS mice. (47; n = 14; DS with vehicle, > 0.02, 0.048. 1.19, 5.09, P = 0.03; DS with CBD, 5.67 ± 1.11, 0.32]. (2.0, 0.045, two-way test; CBD 5; B) Effects of CBD on spontaneous excitatory postsynaptic currents (sEPSCs) recorded in DGCs ([E Cl = −60 mV]), and this reduction was blocked by GABAzine and by TTX (Fig. 3 D and E). The amplitudes of EPSCs were unaffected, consistent with presynaptic effects of CBD (see legend for Fig. 3). Evidently, CBD directly enhances GABA A receptor-mediated inhibition and indirectly reduces excitatory transmission.

CBD Reduces Excitatory Output from the Dentate Gyrus. To directly assess the excitability of DGCs themselves, we recorded APs from DGCs in acutely prepared slices of DS mouse hippocampus using whole-cell patch-clamp recording techniques. During injection of subrheobase depolarizing current to elicit steady generation of APs, treatment with 16 μM CBD reduced the frequency of APs, and this effect was blocked by GABAzine (Fig. 4A). This result indicates that CBD reduces excitatory output from DGCs by enhancing GABA A receptor-mediated inhibition, as expected from the results of Fig. 3.

To assess whether these effects of CBD are caused by directly increasing interneuron excitability, we measured CBD’s effects on AP firing in parvalbumin (PV)-positive fast-spiking interneurons because of their central role in suppressing DGC responses to cortical stimulation (32). CBD reduced rheobase by shifting the upswing of the frequency-stimulus curve to the left below 100 pA (Fig. 4B and Insert). CBD also increased the number of APs elicited by depolarizing current.

(AP)-driven inhibitory postsynaptic currents [sIPSCs (E Cl = 0 mV)]. The frequency of incoming sIPSCs was strikingly reduced in DGCs from DS mice compared with WT, whereas the amplitude was unchanged (16) (Fig. 3 A and B). Thus, DGCs in hippocampal slices from DS mice are a good model system to test effects of CBD on local circuit function.

Treatment with CBD (16 μM), corresponding to the peak brain concentration following a 100 mg/kg p.o. injection in vivo (26), increased the frequency of GABA A receptor-mediated sIPSCs in hippocampal slices from DS mice (Fig. 3 C and E) without affecting the amplitude of the sIPSCs (Fig. 3, legend). Blocking GABA A receptors with the broad-spectrum antagonist GABAzine (10 μM) or blocking APs with tetrodotoxin (TTX; 500 nM) eliminated the effect of CBD (Fig. 3 C and E). These results indicate that CBD increases action potential generation in GABAergic interneurons, which in turn increases the frequency of sIPSCs recorded in DGCs.

Although increased GABAergic transmission to DGCs alone could account for the reduction in their output by CBD, reduced excitatory synaptic input could also be a contributing factor. Increased frequency of inhibitory neurotransmission would be expected to reduce the frequency of excitatory neurotransmission. Consistent with that expectation, CBD reduced the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) recorded in DGCs ([E Cl = −60 mV]), and this reduction was blocked by GABAzine and by TTX (Fig. 3 D and E).

Kaplan et al.  PNAS Early Edition | 3 of 6
CBD Effects Are Independent of CB1 Receptors. CBD is thought to act independently of the canonical cannabinoid receptor CB1, which mediates the functional effects of brain endocannabinoids and the psychotrop effects of Δ9-tetrahydrocannabinol (34). Consistent with this expectation, blocking CB1 receptors with the antagonist, AM281 (1 μM) did not prevent the increase in sIPSCs induced by CBD treatment (Fig. 5). These results suggest that CBD increased sIPSC frequency by increasing AP-dependent GABA release from synaptic vesicles through a CB1-independent mechanism.

CBD Increases Inhibitory Neurotransmission by Blocking GPR55. Given that CBD’s most robust effects are on inhibitory neurons, we next sought to identify the molecular target through which CBD enhances inhibitory signaling. Numerous CBD targets in the brain have been identified (35), including the lipid-activated G protein-coupled receptor GPR55 (36, 37), which is expressed in both interneurons and excitatory neurons in the dentate gyrus and other regions of the hippocampus and modulates hippocampal synaptic plasticity [Allen Brain Atlas (38)]. To determine if CBD antagonism of GPR55 contributed to our observed CBD-induced enhancement of inhibitory signaling, we bath-applied the GPR55 antagonist CID16020046 (CID, 10 μM) (39) and measured the effect of CBD on DGC output and inhibitory neuron signaling. CID (10 μM) alone mimicked the effect of CBD, reducing the frequency of APs generated during injection of subthreshold stimulating current (Fig. 6 A and C). Consistent with CBD antagonism of GPR55, treatment with CBD had no further effect when added in combination with CID, indicating that blockade of GPR55 by this antagonist occluded the reduction in AP generation by CBD (Fig. 6 A and C). Similarly, the enhancement in sIPSC frequency (Fig. 6 B and C) and excitability of PV-positive interneurons (Fig. 6 D) was also occluded in the presence of CID. To further analyze the specificity of the effects of CID, we tested a concentration of output through three mechanisms. At low stimulus levels, CBD reduces rheobase in inhibitory neurons, which would increase their probability of firing trains of APs in response to small depolarizations. Above rheobase, CBD increases frequency of AP generation during trains in interneurons in response to a wide range of stimulus intensities, from rheobase to 400 pA. Finally, CBD decreases the frequency of AP generation of excitatory neurons during periods of high excitatory stimulation at levels (75 pA–400 pA) that are far above rheobase.

To determine whether the reduction in sEPSCs might be caused by a combination of enhanced GABAergic signaling plus reduced intrinsic excitability of excitatory neurons, we measured the effect of CBD on DGC APs using a similar experimental paradigm (Fig. 4 C). CBD had no effect on rheobase but reduced AP frequency at stimulus levels above 75 pA, more than 20-fold higher than rheobase (Fig. 4 C and Inset). This effect may result from direct CBD inhibition of Na+,1.6 channels, as these channels are abundant in excitatory neurons and are inhibited by CBD (33). Treatment with CBD has a selective effect on resurgent sodium currents generated by Na+,1.6, which are thought to drive repetitive action potential firing (33). Recent studies with the atypical sodium channel blocker GS967 show that sodium channel inhibition can be an effective treatment for DS in mice (24). Together, these results suggest that CBD reduces DGC across a wide range of current injection amplitudes (Fig. 4 B), consistent with a significant increase in excitability of inhibitory interneurons.

Fig. 4. Differential effects of CBD on action potential firing in excitatory and inhibitory neurons. (A) Recordings of APs in DGCs (SI Materials and Methods) in the presence of subrheobase current (M = 30.83 ± 5.76 pA, n = 12) in vehicle, CBD (16 μM), or CBD + GBZ. Percent change in frequency: CBD, −58.2 ± 13.1%; t(6) = −4.44, P = 0.01, n = 5; CBD + GBZ, 11.6 ± 23.5%; t(6) = 0.50, P = 0.64, n = 7, one-sample t test). (B) Percentage maximum AP frequency in the presence of vehicle (blue) or 16 μM CBD (red) with increasing current injection in PV-positive interneurons identified with td-Tomato fluorescence (SI Materials and Methods). (Inset) Current-clamp recordings at 75 pA injection amplitude. Rheobase: DS + vehicle: 121.7 ± 19.4 pA, n = 6; DS + CBD: 95 ± 19.5 pA, n = 6, t(5) = 2.61, P = 0.048, paired-t test. CBD increased AP frequency at increasing current injection amplitudes [main effect of condition, F(1,200) = 7.87, P = 0.04, repeated-measures ANOVA]. (C) Percentage maximum AP frequency in vehicle (blue) or 16 μM CBD (red) at increasing current injection steps in DGCs. Rheobase: vehicle: 20.8 ± 4.0 pA; CBD: 16.7 ± 3.3 pA, n = 6, P = 0.4, CBD reduced. AP firing frequency [main effect of condition, F(1,120) = 12.65, P = 0.04, two-way repeated-measures ANOVA]. *P < 0.05.
Fig. 6. Role of GPR55 in the CBD-induced increase in inhibitory transmission. (A) Current-clamp recordings of DGCs (SI Materials and Methods) in the presence of subthreshold-stimulating current (M = 28.0 ± 10.0 pA, n = 10). (B) Voltage-clamp recordings (Vh = −60 mV) of DGC sIPSCs (EC2 = 0 mV; SI Materials and Methods) in CID16020064 (CID, 10 μM) or CBD (16 μM) in the presence of CID, the AMPA receptor antagonist CNQX (20 μM), and the NMDA receptor antagonist APV (50 μM). Asterisks indicate sIPSC. (C) Percentage change in AP frequency: CID 10 μM, −44.18 ± 11.1%, (t(9)) = 4.00, P = 0.003, n = 10; CID (10 μM) + CBD, −9.8 ± 15.2%, n = 9, (t(8)) = 0.64, P = 0.64, one-sample t-test. Percentage change in IPSC frequency: 10 μM CID, 16.4 ± 9.3%, n = 9, (t(8)) = 1.77, P = 0.1. CID 10 μM blocked the CBD-induced enhancement of sIPSC frequency [−6.74 ± 7.42%, n = 9, (t(8)) = 0.39, one-sample t test], CID (1 μM), 27.9 ± 9.3%, n = 9, (t(8)) = −3.00, P = 0.02. CID (1 μM) also blocked the CBD-induced enhancement of sIPSC frequency [2.54 ± 12.4%, n = 11, (t(10)) = 0.21, P = 0.84]. (D) Percentage maximum AP frequency in 10 μM CID (blue) or 16 μM CBD (red) at increasing current injection steps in PV-positive interneurons identified with tdTomato fluorescence. Rheobase: vehicle, 64.0 ± 9.27 pA, n = 5; CBD: 62.0 ± 5.83, n = 5; (t(4)) = 0.54, P = 0.62, paired t test. CID blocked the effect of CBD on AP frequency (main effect of condition, F(1,160) = 2.31, P = 0.20, repeated-measures ANOVA). *P < 0.05, **P < 0.01.

1 μM on spontaneous sIPSCs. Even at this much lower concentration, CID substantially increased the frequency of sIPSCs and occluded the effects of CBD (Fig. 6C). CID is selective for inhibition of GPR55 at 1 μM and 10 μM compared with many other potential cellular targets (SI Discussion). Together, these mechanistic studies reveal that CBD increases inhibitory neuron excitability in substantial part through antagonism of GPR55.

Discussion

With increasing access to medicinal cannabis, many will seek CBD-rich extracts for treating DS and other debilitating epilepsies, despite limited scientific support of their efficacy. Parents of children with DS have moved their families to states in the United States where medical cannabis is available to provide treatment (2). Recent clinical trials support CBD’s treatment potential against seizures in patients with DS (6, 7), showing efficacy of CBD in reducing seizure frequency in DS. These results are encouraging, but considering the diversity of patient age, background, and standard-of-care medications, these clinical studies do not yet provide quantitative measures of CBD’s effects on seizure generation or other comorbid symptoms of DS in the absence of potentially confounding variables.

In our experiments, the subject mice are genetically identical; they have no standard-of-care treatments; and seizure duration, frequency, and severity are measured in a blinded, objective manner. Therefore, our study provides strong preclinical evidence for CBD’s efficacy in reducing seizure frequency, as observed in DS patients (6, 7), and extends these findings by providing quantitative evidence of CBD efficacy on seizure duration and severity. These results provide further strong impetus for exploring the therapeutic benefit of CBD on the core behavioral symptoms of DS and other medically refractory epilepsy syndromes.

In DS, convulsive seizures may continue in adulthood, although their frequency and severity decreases and they become more responsive to pharmacological treatments (9). Unfortunately, DS patients in their teenage years and beyond suffer from severe cognitive deficits and autistic-like behaviors (9, 10). There are no reports of CBD’s efficacy in treating autism; however, a human clinical trial is currently underway (Identifier: NCT02956226). We found that CBD increased time spent in social interaction using two separate social behavior paradigms and reduced the frequency of defensive escape behavior. Thus, our results provide an initial indication that CBD treatment might be beneficial for treating autism-like social deficits caused by mutations in sodium channels.

A high dose of CBD (100 mg/kg) is needed to protect against seizures, while low doses (10–20 mg/kg) improve social behaviors in DS mice, and these beneficial effects are lost at higher doses. These findings present a conundrum for designing treatments of DS that both control seizures and improve social behavior. We found a similar discrepancy between the high doses of clozapine required for seizure control and the low doses that are necessary for improved cognition and social behavior in DS mice and another mouse model of autism (16, 18). In that case, preferential drug effects on GABA_A receptors having α2 and or α3 subunits may be beneficial for treatment of cognitive and social interaction deficits, whereas effects on α1 subunit-containing GABA_A receptors prevent seizures but induce substantial sedation. It is conceivable that the effects of low-dose CBD and high-dose CBD may also reflect actions on different molecular mechanisms. Our studies point to GPR55 as the molecular target for high doses of CBD that are effective in control of seizures.

A major benefit of studies of CBD in a well-validated animal model is the ability to probe its mechanism of action. We have taken two important steps in that direction here. First, we find that CBD balances the ratio of excitation to inhibition in the hippocampus of DS mice. The decrease in interneuron rheobase for generation of trains of APs may be the dominant effect because it would provide more immediate and effective response of the inhibitory neurons to increases in excitatory input. These results suggest that CBD acts on the core deficit in DS, which is failure of firing of GABAergic interneurons (13, 21). Furthermore, we find that pharmacological control over impaired inhibitory signaling can be achieved by CBD antagonism of GPR55. It has been shown that CBD antagonizes GPR55 in transfected cells (36), and our results extend these findings to intact neurons in brain slices. We show that antagonism of GPR55 occludes CBD’s actions and mimics CBD’s enhancement of inhibitory transmission to DGCs and reduction of spontaneous APs of DGCs. Since the reduction in excitatory transmission by CBD was blocked by the broad-spectrum GABA_A antagonist GABAzine, antagonism of GPR55 by CBD may dampen spontaneous excitatory transmission by increasing inhibition. Therefore, CBD antagonism of GPR55 in the dentate gyrus likely affects inhibitory transmission directly. This mechanism of action holds much promise for future drug development aimed at GPR55 and its downstream signaling pathways. Unfortunately, the GPR55 antagonist used here (CID16020046) does not enter the central nervous system efficiently in vivo, and future studies are therefore required to assess the effect of GPR55 antagonists injected in vivo.

In addition to rescue of GABAergic signaling in DS mice, we find that CBD reduces the excitability of DGCs following high-current injection amplitudes well above rheobase, consistent with stimulus levels that may be observed during seizures. The combination
of CBD’s antipodal effects on interneuron and DGC excitability (i.e., enhancement vs. reduction, respectively) may provide a mechanistic explanation for improvement in seizure characteristics by CBD treatment. By enhancing GABAergic inhibition of DGCs, CBD may reduce the likelihood of seizures occurring. However, when excitatory transmission increases during thermal induction and seizure occurrence is inevitable, CBD reduction in DGC excitability may dampen the severity of the seizure and shorten its duration. These dual actions of CBD make it a promising antiepileptic strategy in an otherwise medically resistant disorder. Coupled with its relatively low side-effect profile compared with other antiepileptic drugs (5–7), the emerging data supporting efficacy of CBD in treatment-resistant epilepsies holds great promise for improved therapy of these devastating diseases.

Materials and Methods

All procedures conform to the regulations detailed in the National Institute of Health’s Guide for the Care and Use of Laboratory Animals (40) and were approved by the Institutional Animal Care and Use Committee at the University of Washington. Scn1a mutant mice were generated (13), seizures were thermally induced (15), spontaneous seizures were measured (25), and social interaction tests were carried out (16) using previously described procedures. KA are presented in Materials and Methods. Hippocampi were prepared and electrophysiological recordings were made using previously described methods (16, 18) that are presented in SI Materials and Methods. CBD (GW Pharmaceuticals) was dissolved in a vehicle solution (1% ethanol:1% cremophore:18% saline) and used for up to 1 wk. The SR 95531 hydrobromide (GABAzine), tetrodotoxin, and CID16020046 were purchased from Tocris Bioscience.

ACKNOWLEDGMENTS. We thank Dr. Ben Whalley (University of Reading), Dr. Orrin Devinsky (New York University), and scientists at GW Pharmaceuticals for valuable discussions that led to our development of this research project; GW Pharmaceuticals for a generous supply of CBD; Jeremy Bazinet (University of Washington) for early experiments on thermal induction of seizures; and Kate Swinney (University of Washington) for help with CBD supply. We acknowledge generous research support from the Alcohol and Drug Abuse Institute at the University of Washington (Grant ADA1-1016-12 to J.S.K.); Citizens United for Cure of Epilepsy (CURE) (R.E.W.); the NIH National Institute of Neurological Disorders and Stroke (Grant R01 NS025704 to W.A.C.); and the NIH National Institute on Drug Abuse (Grant R01 DA026430 to N.S.).